SOS-AMI

A multicentric, double-blind, randomised, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of subcutaneous selatogrel administered alone in the prevention of all-cause mortality and in the treatment of acute myocardial infarction in participants who have recently had an acute myocardial infarction.